BACKGROUND: Eosinophilic inflammation is implicated in asthma. Eotaxin 1-3 regulate eosinophil trafficking into the airways along with other chemotactic factors. However, the epithelial and bronchoalveolar lavage (BAL) cell expression of these chemokines in relation to asthma severity and eosinophilic phenotypes has not been addressed. OBJECTIVE: To measure the expression of the three eotaxin isoforms in bronchoscopically obtained samples and compare them with clinically relevant parameters between normal subjects and patients with asthma. METHODS: Normal subjects and patients with asthma of varying severity recruited through the Severe Asthma Research Program underwent clinical assessment and bronchoscopy with airway brushing and BAL. Eotaxin 1-3 mRNA/protein were measured in epithelial and BAL cells and compared with asthma severity, control and eosinophilic inflammation. RESULTS: Eotaxin-2 and eotaxin-3 mRNA and eotaxin-2 protein were increased in airway epithelial brushings from patients with asthma and were highest in cases of severe asthma (p values 0.0155, 0.0033 and 0.0006, respectively), with eotaxin-2 protein increased with age at onset. BAL cells normally expressed high levels of eotaxin-2 mRNA/protein but BAL fluid levels of eotaxin-2 were lowest in severe asthma. Epithelial eotaxin-2 and eotaxin-3 mRNA/protein was associated with sputum eosinophilia, lower forced expiratory volume in 1 s and more asthma exacerbations. Airway epithelial cell eotaxin-2 protein differed by asthma severity only in those with late onset disease, and tended to be highest in those with late onset eosinophilic asthma. CONCLUSIONS: Epithelial eotaxin-2 and 3 are increased in asthma and severe asthma. Their expression may contribute to luminal migration of eosinophils, especially in later onset disease, asthma control and severity.
BACKGROUND:Eosinophilic inflammation is implicated in asthma. Eotaxin 1-3 regulate eosinophil trafficking into the airways along with other chemotactic factors. However, the epithelial and bronchoalveolar lavage (BAL) cell expression of these chemokines in relation to asthma severity and eosinophilic phenotypes has not been addressed. OBJECTIVE: To measure the expression of the three eotaxin isoforms in bronchoscopically obtained samples and compare them with clinically relevant parameters between normal subjects and patients with asthma. METHODS: Normal subjects and patients with asthma of varying severity recruited through the Severe Asthma Research Program underwent clinical assessment and bronchoscopy with airway brushing and BAL. Eotaxin 1-3 mRNA/protein were measured in epithelial and BAL cells and compared with asthma severity, control and eosinophilic inflammation. RESULTS:Eotaxin-2 and eotaxin-3 mRNA and eotaxin-2 protein were increased in airway epithelial brushings from patients with asthma and were highest in cases of severe asthma (p values 0.0155, 0.0033 and 0.0006, respectively), with eotaxin-2 protein increased with age at onset. BAL cells normally expressed high levels of eotaxin-2 mRNA/protein but BAL fluid levels of eotaxin-2 were lowest in severe asthma. Epithelial eotaxin-2 and eotaxin-3 mRNA/protein was associated with sputum eosinophilia, lower forced expiratory volume in 1 s and more asthma exacerbations. Airway epithelial cell eotaxin-2 protein differed by asthma severity only in those with late onset disease, and tended to be highest in those with late onset eosinophilic asthma. CONCLUSIONS: Epithelial eotaxin-2 and 3 are increased in asthma and severe asthma. Their expression may contribute to luminal migration of eosinophils, especially in later onset disease, asthma control and severity.
Authors: Jinming Zhao; Valerie B O'Donnell; Silvana Balzar; Claudette M St Croix; John B Trudeau; Sally E Wenzel Journal: Proc Natl Acad Sci U S A Date: 2011-08-09 Impact factor: 11.205
Authors: S Matsukura; C Stellato; S N Georas; V Casolaro; J R Plitt; K Miura; S Kurosawa; U Schindler; R P Schleimer Journal: Am J Respir Cell Mol Biol Date: 2001-06 Impact factor: 6.914
Authors: C M Lilly; H Nakamura; O I Belostotsky; K J Haley; E A Garcia-Zepeda; A D Luster; E Israel Journal: Am J Respir Crit Care Med Date: 2001-06 Impact factor: 21.405
Authors: Silvana Balzar; Merritt L Fajt; Suzy A A Comhair; Serpil C Erzurum; Eugene Bleecker; William W Busse; Mario Castro; Benjamin Gaston; Elliot Israel; Lawrence B Schwartz; Douglas Curran-Everett; Charity G Moore; Sally E Wenzel Journal: Am J Respir Crit Care Med Date: 2010-09-02 Impact factor: 21.405
Authors: Mario Castro; Sameer Mathur; Frederick Hargreave; Louis-Philippe Boulet; Fang Xie; James Young; H Jeffrey Wilkins; Timothy Henkel; Parameswaran Nair Journal: Am J Respir Crit Care Med Date: 2011-08-18 Impact factor: 21.405
Authors: Wendy C Moore; Michael D Evans; Eugene R Bleecker; William W Busse; William J Calhoun; Mario Castro; Kian Fan Chung; Serpil C Erzurum; Douglas Curran-Everett; Raed A Dweik; Benjamin Gaston; Mark Hew; Elliot Israel; Martin L Mayse; Rodolfo M Pascual; Stephen P Peters; Lori Silveira; Sally E Wenzel; Nizar N Jarjour Journal: J Allergy Clin Immunol Date: 2011-04-15 Impact factor: 10.793
Authors: Jennifer M Bratt; Kevin Y Chang; Michelle Rabowsky; Lisa M Franzi; Sean P Ott; Simone Filosto; Tzipora Goldkorn; Muhammad Arif; Jerold A Last; Nicholas J Kenyon; Amir A Zeki Journal: J Immunol Date: 2018-04-27 Impact factor: 5.422
Authors: Min Xie; Anthony T Mustovich; Yi Jiang; John B Trudeau; Anuradha Ray; Prabir Ray; Haizhen Hu; Fernando Holguin; Bruce Freeman; Sally E Wenzel Journal: J Allergy Clin Immunol Date: 2014-10-11 Impact factor: 10.793
Authors: Diego Bagnasco; Matteo Ferrando; Marco Caminati; Alice Bragantini; Francesca Puggioni; Gilda Varricchi; Giovanni Passalacqua; Giorgio Walter Canonica Journal: Drug Saf Date: 2017-07 Impact factor: 5.606
Authors: Behzad Yeganeh; Emilia Wiechec; Sudharsana R Ande; Pawan Sharma; Adel Rezaei Moghadam; Martin Post; Darren H Freed; Mohammad Hashemi; Shahla Shojaei; Amir A Zeki; Saeid Ghavami Journal: Pharmacol Ther Date: 2014-02-26 Impact factor: 12.310
Authors: Adriana L da Silva; Sabrina V Martini; Soraia C Abreu; Cynthia dos S Samary; Bruno L Diaz; Sandra Fernezlian; Vanessa Karen de Sá; Vera Luiza Capelozzi; Nicholas J Boylan; Rodolfo Gustavo Goya; Jung Soo Suk; Patricia R M Rocco; Justin Hanes; Marcelo M Morales Journal: J Control Release Date: 2014-02-17 Impact factor: 9.776
Authors: Eva M Sturm; Kimberly D Dyer; Caroline M Percopo; Akos Heinemann; Helene F Rosenberg Journal: Eur J Immunol Date: 2013-06-14 Impact factor: 5.532